



Press Release |

PROcURE TREATMENT CENTERS, INC. CLOSES THE FINANCING OF ITS IBA PROTON THERAPY CENTER TO BE INSTALLED IN OKLAHOMA CITY

Louvain-la-Neuve, Belgium, April 25, 2007 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) announced today that financing has been secured for construction of a \$95 million proton therapy center in Oklahoma City. The 55,000-square-foot facility being developed by ProCure Treatment Centers will include installation of an advanced proton therapy system from IBA valued at about \$50 million.

Senior debt and mezzanine financing was secured through IBA and ProCure's collaboration with two world-class financial institutions, Fortis and KBC (Belgium). The Oklahoma City installation will have little financial impact on IBA's performance in 2007. It should essentially affect fiscal years 2008 and 2009.

The Oklahoma ProCure Treatment Center will be the first owned by ProCure, and the first-ever proton therapy cancer treatment center in the United States to be owned and operated by physicians.. It will house four treatment rooms, including two inclined-beam rooms, one fixed-horizontal-beam room and a 360-degree gantry treatment room. The first cancer patient is expected to be treated at the ProCure proton therapy center in 2009.

"There are no radiation cancer treatments in the world today as precise and effective as proton therapy," said Hadley Ford, chief executive officer of ProCure, which is based in Bloomington, Ind. "Financing our OKC facility ensures we can provide a world-class cancer treatment facility for the people of Oklahoma City and utilize world-class therapeutic equipment from IBA. Having completed installation of more than half of the proton therapy systems in the world, IBA was the only partner to consider in such a critical venture." The center is built for a group of seven doctors from Radiation Medicine Associates (RMA) and Radiation Oncology Associates (ROA), two leading radiation oncology practices in Oklahoma City which have partnered with ProCure Treatment Centers, Inc.

"IBA is excited about bringing the incredible cancer-fighting benefits of proton therapy to the people of Oklahoma," said Pierre Mottet, IBA's chief executive officer. "The ProCure facility will place it among a select group of institutions at the vanguard of cancer treatment. Proton Therapy is now turning quickly into a very demanded clinical modality, yet, building a center is challenging and money at stake is unusually high in the Radiation Therapy industry, even for small, single room centers. With over 50 % market share and several systems treating patients every day in the world while our competitors are still struggling to make their prototype work, IBA is the clear safe bet and the only proven cyclotron based system supplier in the world. We are delighted to be given the opportunity to make Proton Therapy available to the people of Oklahoma and to be part of the first Proton Therapy private practice in the US."



Press Release |

IBA is the undisputed world market leader in proton therapy, with over 50 % market share. Twelve institutions in the United States, Asia and Europe have already selected a proton therapy system from IBA. The IBA Particle Therapy product line ranges from small, one- room compact systems to top- of- the- line carbon configurations. IBA is the only company that has regulatory clearances, including FDA clearance to market cyclotron- based particle therapy systems.

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com